As the race to develop targeted therapies continues, pharmaceutical companies seek to create a competitive advantage by developing new treatments for actionable biomarkers.
The clinical trial's success is strongly dependent on a company's ability to recruit eligible patients with a higher predictive responsiveness factor.
It is estimated that up to 80% of clinical trials fail to meet enrollment timelines, while 26% of rare diseases trials are terminated because of low accrual rates
lmagene is pharma's first choice for an optimized drug development, clinical trials design and enrollment,
and companion diagnostics solutions
Optimized clinical trial enrollment, design, and success
AI-enabled Companion Diagnostics for Precision Oncology
Drug Development Optimization